Q1 Earnings Estimate for Alumis Issued By Leerink Partnrs

Alumis Inc. (NASDAQ:ALMS) – Stock analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Alumis in a research report issued to clients and investors on Sunday, March 23rd. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings of ($1.46) per share for the quarter. The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share.

ALMS has been the subject of several other research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Alumis in a report on Thursday, March 20th. HC Wainwright reiterated a “buy” rating and set a $15.00 target price (down previously from $19.00) on shares of Alumis in a research report on Thursday, March 20th. Finally, Oppenheimer began coverage on shares of Alumis in a report on Thursday, January 30th. They set an “outperform” rating and a $32.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $26.00.

Alumis Price Performance

Shares of ALMS stock opened at $4.00 on Tuesday. Alumis has a 1 year low of $3.18 and a 1 year high of $13.53. The firm has a fifty day moving average price of $5.55 and a 200-day moving average price of $8.43.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Foresite Capital Management V LLC boosted its stake in Alumis by 3.5% in the fourth quarter. Foresite Capital Management V LLC now owns 5,779,348 shares of the company’s stock valued at $45,426,000 after acquiring an additional 194,459 shares in the last quarter. Foresite Capital Management VI LLC acquired a new position in Alumis during the 4th quarter valued at about $33,033,000. Samsara BioCapital LLC purchased a new stake in Alumis in the third quarter valued at about $34,886,000. Tang Capital Management LLC boosted its holdings in Alumis by 40.6% in the fourth quarter. Tang Capital Management LLC now owns 600,000 shares of the company’s stock worth $4,716,000 after acquiring an additional 173,406 shares in the last quarter. Finally, Ally Bridge Group NY LLC grew its stake in shares of Alumis by 6.4% during the fourth quarter. Ally Bridge Group NY LLC now owns 445,259 shares of the company’s stock worth $3,500,000 after acquiring an additional 26,843 shares during the last quarter.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.